CTIS2023-509268-26-00招募中1 期
EVOLVE-MI: A Pragmatic Randomized Multicenter Trial of EVOLocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized With Acute Myocardial Infarction - 20190184
Amgen Inc.0 个研究点目标入组 6,000 人开始时间: 2024年3月25日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 6,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Subject has provided informed consent/assent prior to initiation of any study specific activities/procedures; OR, subject’s legally authorized representative has provided informed consent prior to any study-specific activities/procedures being initiated when the subject has any kind of condition that, in the opinion of the Investigator, may compromise the ability of the subject to give written informed consent., Age = 18 years (eg, if no upper age limit)., Hospitalized for primary reason of NSTEMI or STEMI due to presumed atherosclerotic disease.
排除标准
- •Patients requiring invasive hemodynamic and/or vasopressor/inotropic support at the time of screening, Subject has known sensitivity to any of the products or components to be administered during dosing., Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures (eg, Clinical Outcome Assessments) to the best of the subject and investigator’s knowledge., History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion., Patients with elevated biomarkers of myocardial injury due to secondary/nonatherosclerotic etiology (eg, sepsis, atrial fibrillation, vasospasm, decompensated heart failure, uncontrolled hypertension, stress induced cardiomyopathy)., History or evidence of clinically significant disease (eg, malignancy, respiratory, gastrointestinal, renal or psychiatric disease) or unstable disorder that, in the opinion of the investigator(s), Amgen physician or designee would pose a risk to the patient’s safety or interfere with the study assessments, procedures, completion, or result in a life expectancy of less than 1 year., Previously received or receiving any therapy to inhibit PCSK9 in the following timeframe: • Evolocumab, alirocumab, or any other monoclonal antibody against PCSK9 within 3 months prior to screening. • Inclisiran within 6 months prior to screening., Currently receiving treatment in another investigational (not approved for any use in the country the subject is to be randomized) device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded., Female subjects of childbearing potential unwilling to use protocol specified method of contraception see Appendix 5 (Section 11.5) during treatment and for an additional 15 weeks after the last dose of investigational product., Female subjects who are breastfeeding or who plan to breastfeed while on study through 15 weeks after the last dose of investigational product., Female subjects planning to become pregnant while on study through 15 weeks after the last dose of investigational product., Female subjects of childbearing potential with a positive pregnancy test assessed at screening by a highly sensitive urine or serum pregnancy test.
研究者
相似试验
进行中（未招募）
1 期
Impact of Early Evolocumab Administration on Cardiovascular Events after Acute Myocardial InfarctioDyslipidemiaEUCTR2021-005272-19-SEAmgen Inc6,000
进行中（未招募）
1 期
Clinical study phase III, first line treatment of patients with lung cancercomparing investigational drug M7824 vs Pembrolizumab.EUCTR2018-001517-32-BEMerck Healthcare KGaA584
进行中（未招募）
1 期
Clinical study phase III, first line treatment of patients with lung cancer comparing investigational drug M7824 vs Pembrolizumab.EUCTR2018-001517-32-DEMerck Healthcare KGaA584
尚未招募
3 期
Effect of Herbal tablet Pinak on HIV, Hepatitis B and HEPATITIS C corona virusesCTRI/2021/10/037309Sudesh Shiva Devadiga
已完成
3 期
A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)JPRN-jRCT2031220468Gesine Respondek, M.D.24